Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Galecto Inc. (GLTO)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 25,260,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Galecto is a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Co.'s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. Co.'s primary product candidate, GB0139, is an inhaled inhibitor of galectin-3. Co. is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 1,142 1,142 3,215 1,269,195
Total Sell Value $3,863 $3,863 $15,480 $1,842,434
Total People Sold 3 3 3 4
Total Sell Transactions 3 3 6 10
End Date 2025-04-13 2025-01-10 2024-07-12 2023-07-13

   
Records found: 49
  Page 1 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Schambye Hans T. Chief Executive Officer   •       •      –    2025-07-03 4 S $3.38 $2,484 D/D (735) 4,022     -
   Schambye Hans T. Chief Executive Officer   •       •      –    2025-07-03 4 OE $0.00 $0 D/D 1,360 4,757     -
   Winslow Garrett General Counsel   •       –      –    2025-07-03 4 S $3.39 $881 D/D (260) 1,429     -
   Winslow Garrett General Counsel   •       –      –    2025-07-03 4 OE $0.00 $0 D/D 680 1,689     -
   Firmani Lori Interim CFO   •       –      –    2025-07-03 4 S $3.39 $498 D/D (147) 692     -
   Firmani Lori Interim CFO   •       –      –    2025-07-03 4 OE $0.00 $0 D/D 374 839     -
   Schambye Hans T. Chief Executive Officer   •       •      –    2025-01-03 4 S $5.60 $7,510 D/D (1,341) 3,397     -
   Schambye Hans T. Chief Executive Officer   •       •      –    2025-01-03 4 OE $0.00 $0 D/D 2,640 4,738     -
   Winslow Garrett General Counsel   •       –      –    2025-01-03 4 S $5.60 $2,638 D/D (471) 1,009     -
   Winslow Garrett General Counsel   •       –      –    2025-01-03 4 OE $0.00 $0 D/D 1,320 1,480     -
   Firmani Lori Interim CFO   •       –      –    2025-01-03 4 S $5.63 $1,469 D/D (261) 465     -
   Firmani Lori Interim CFO   •       –      –    2025-01-03 4 OE $0.00 $0 D/D 726 726     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-08-15 4 S $0.75 $617,010 I/I (822,680) 1,510,375     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-07-31 4 S $3.00 $628,200 I/I (209,400) 2,105,909     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-07-25 4 S $2.92 $114,464 I/I (39,200) 2,258,987     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-07-13 4 S $2.40 $467,280 I/I (194,700) 2,285,687     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-17 4 S $1.97 $25,785 I/I (13,089) 2,417,787     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-14 4 S $1.86 $77,090 I/I (41,446) 2,426,665     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-13 4 S $1.82 $25,382 I/I (13,946) 2,454,775     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-12 4 S $1.81 $4,277 I/I (2,363) 2,464,234     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-11 4 S $1.82 $25,382 I/I (13,946) 2,465,837     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-10 4 S $1.79 $91,698 I/I (51,228) 2,500,582     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-06 4 S $2.00 $19,330 I/I (9,665) 2,510,041     -
   Orbimed Capital Gp Vii Llc 10% Owner   –       –       •   2023-04-05 4 S $2.18 $202,664 I/I (92,965) 2,516,599     -
   Lindmark Bertil Chief Medical Officer   •       –      –    2022-03-22 4 B $2.16 $31,545 D/D 14,604 16,604 2.74     -
  49 Records found
  1  2   
  Page 1 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us